Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03422393
Title Venetoclax With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Michael Choi
Indications

CLL/SLL

chronic lymphocytic leukemia

Therapies

Ibrutinib + Venetoclax

Venetoclax

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.